MedTrace Logo

Cetuximab and Lenalidomide in Head and Neck

NCT01133665 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2014-11-24

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to study specific FcRIIIa polymorphisms and their correlation with clinical outcome in subjects treated with cetuximab and lenalidomide.

Conditions

Interventions

DRUG

Cetuximab and Lenalidomide

The treatment of Head and Neck Cancer with Cetuximab and Lenalidomide

Sponsors & Collaborators

  • Celgene Corporation

    collaborator INDUSTRY

  • University of Chicago

    lead OTHER

Principal Investigators

  • Everett Vokes, M.D. · University of Chicago

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2011-08-31
Completion
2012-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01133665 on ClinicalTrials.gov